Loading
A phase 2/3 trial testing SPH4336 in HR-positive / HER2-negative breast cancer, now recruiting.
Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer is a phase 2/3 interventional study registered as NCT05744687, led by Shanghai Pharmaceuticals, and recruiting on the registry. Official title: Randomised, Double-blind, Placebo-controlled, Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer. Planned enrolment is 374 participants (estimated). The study started in 2023-04-24 and primary completion is expected in 2026-05-31. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/